Biofunctional coacervate-based artificial protocells with membrane-like and cytoplasm-like structures for the treatment of persistent hyperuricemia
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2023.11.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Qian Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Artificial Cells, Hyperuricemia. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province, National Natural Science Foundation of China, Huazhong University of Science and Technology.
Abstract (Originalsprache)
Coacervate droplets formed by liquid-liquid phase separation have attracted considerable attention due to their ability to enrich biomacromolecules while preserving their bioactivities. However, there are challenges to develop coacervate droplets as delivery vesicles for therapeutics resulting from the lack of physiological stability and inherent lack of membranes in coacervate droplets. Herein, polylysine-polynucleotide complex coacervate droplets with favorable physiological stability are formulated to efficiently and facilely concentrate small molecules, biomacromolecules and nanoparticles without organic solvents. To improve the biocompatibility, the PEGylated phospholipid membrane is further coated on the surface of the coacervate droplets to prepare coacervate-based artificial protocells (ArtPC) with membrane-like and cytoplasm-like structures. The ArtPC can confine the cyclic catalytic system of uricase and catalase inside to degrade uric acid and deplete the toxicity of H2O2. This biofunctional ArtPC effectively reduces blood uric acid levels and prevents renal injuries in mice with persistent hyperuricemia. The ArtPC-based therapy can bridge the disciplines of synthetic biology, pharmaceutics and therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China.
- Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: yuanyuanguo@mail.hust.edu.cn.
- Tongji School of Pharmacy, Huazhong University of Science and Technology, Wuhan 430030, China; Hubei Engineering Research Centre for Novel Drug Delivery System, Wuhan 430030, China. Electronic address: zhipingzhang@mail…
Förderung
- Natural Science Foundation of Hubei Province
- National Natural Science Foundation of China
- Huazhong University of Science and Technology
Zitieren
APA
Hu, Q., Lan, H., Tian, Y., Li, X., Wang, M., Zhang, J., Yu, Y., Chen, W., Kong, L., Guo, Y., & Zhang, Z. (2024). Biofunctional coacervate-based artificial protocells with membrane-like and cytoplasm-like structures for the treatment of persistent hyperuricemia. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.11.030
Vancouver
Hu Q, Lan H, Tian Y, Li X, Wang M, Zhang J, et al. Biofunctional coacervate-based artificial protocells with membrane-like and cytoplasm-like structures for the treatment of persistent hyperuricemia. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2023.11.030
BibTeX
@article{Hu2024,
author = {Hu, Qian and Lan, Hongbing and Tian, Yinmei and Li, Xiaonan and Wang, Mengmeng and Zhang, Jiao and Yu, Yulin and Chen, Wei and Kong, Li and Guo, Yuanyuan and Zhang, Zhiping},
title = {Biofunctional coacervate-based artificial protocells with membrane-like and cytoplasm-like structures for the treatment of persistent hyperuricemia},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2023.11.030}
}
EUVIMED